The drug-placebo response curve: a new method for assessing drug effects in clinical trials.

Abstract:

:Unlike many other areas of medicine, psychiatric clinical trials have no gold standard laboratory tests with which to measure drug effects. Although reliable and valid psychometric measures are available, the standard analysis of such measures obscures the clinical relevance of drug effects. In this study, the authors sought to address this problem by developing a graphical display called the drug-placebo response curve. The features of the drug-placebo response curve are described by applying it to a previously published, controlled clinical trial of desipramine in the treatment of adults with attention-deficit/hyperactivity disorder. Unlike the standard analysis, the drug-placebo response curve showed that desipramine was effective over the full range of response and that it prevented worsening, in addition to increasing the likelihood of improvement. The drug-placebo response curve provides clinically relevant information about the effect of drugs on continuous outcomes in controlled clinical trials.

journal_name

J Clin Psychopharmacol

authors

Faraone SV,Biederman J,Spencer TJ,Wilens TE

doi

10.1097/00004714-200012000-00014

subject

Has Abstract

pub_date

2000-12-01 00:00:00

pages

673-9

issue

6

eissn

0271-0749

issn

1533-712X

journal_volume

20

pub_type

杂志文章
  • An open clinical trial of fluoxetine in the treatment of premature ejaculation.

    abstract::There have been an increased number of recent reports on orgasm-related sexual dysfunction coincident with selective serotonin reuptake inhibitor (SSRI) treatment. In contrast, it has also been reported that SSRIs improve sexual dysfunction. Low doses of clomipramine and paroxetine, potent 5-hydroxytryptamine reuptake...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199610000-00006

    authors: Lee HS,Song DH,Kim CH,Choi HK

    更新日期:1996-10-01 00:00:00

  • Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.

    abstract::Adverse events during selective serotonin reuptake inhibitor (SSRI) treatment are frequent and may lead to premature treatment discontinuation. If attrition is associated with early worsening of adverse effects or the frequency, intensity, or burden of adverse effects, interventions to maximize retention could be focu...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/JCP.0b013e3181dbfd04

    authors: Warden D,Trivedi MH,Wisniewski SR,Kurian B,Zisook S,Kornstein SG,Friedman ES,Miyahara S,Leuchter AF,Fava M,Rush AJ

    更新日期:2010-06-01 00:00:00

  • Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates.

    abstract::The cholinergic-adrenergic balance hypothesis of affective disorders suggests that, in the areas of the brain that regulate mood, depression may represent a relative predominance of central cholinergic tone over adrenergic tone and that mania may represent the converse. Currently, converging lines of investigation fro...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-198107000-00003

    authors: Risch SC,Kalin NH,Janowsky DS

    更新日期:1981-07-01 00:00:00

  • Malpractice and tardive dyskinesia: a conceptual dilemma.

    abstract::This discussion focuses on three basic areas relevant to tardive dyskinesia (TD). The first area includes an overview of some specific acts of negligence that have been the basis for successful malpractice cases involving TD. Some of these acts of negligence include inappropriate assessment of the patient, failure to ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-198808001-00014

    authors: Tancredi LR

    更新日期:1988-08-01 00:00:00

  • Symptom comorbidity in anxiety and depressive disorders.

    abstract::The ability of the Hamilton Rating Scale for Anxiety, the Hamilton Rating Scale for Depression, and 50 items from the self-rated Hopkins Symptom Checklist to discriminate generalized anxiety disorder from major depressive disorder was examined for over 3,000 patients entering studies in three drug development projects...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199006001-00011

    authors: Copp JE,Schwiderski UE,Robinson DS

    更新日期:1990-06-01 00:00:00

  • Implementation and Outcomes of a Clozapine-Associated Myocarditis Screening Program in a Region of South Australia-Lessons Learned.

    abstract:PURPOSE:Clozapine-associated myocarditis (CAM) is a serious complication, mostly occurring in the first month of treatment. Public mental health in South Australia introduced a screening protocol in 2011 using baseline and weekly C-reactive protein and troponin. The aim of this study was to assess protocol adherence an...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001193

    authors: Nachmani Major N,Dawson BPharm Hons JL,Clark SR

    更新日期:2020-05-01 00:00:00

  • Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.

    abstract::The optimal treatment for schizoaffective disorder (SCA) is not well established. In this initial 6-month open-label treatment period of a large, multiphase, relapse-prevention study, the efficacy and safety of paliperidone palmitate once-monthly (PP1M) injectable were evaluated in subjects with symptomatic SCA. Subje...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000535

    authors: Fu DJ,Turkoz I,Simonson RB,Walling D,Schooler N,Lindenmayer JP,Canuso C,Alphs L

    更新日期:2016-08-01 00:00:00

  • The evolution of treatment resistance: biologic implications.

    abstract::The evolution of resistance of positive symptoms to antipsychotic therapy may represent a valuable means of subtyping schizophrenia. In contrast, resistance of negative symptoms and cognitive function to antipsychotic agents seems to be present from the first episode of psychotic symptoms and does not evolve over time...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-199804001-00003

    authors: Meltzer HY,Lee M,Cola P

    更新日期:1998-04-01 00:00:00

  • The Utility of Low-Dose Aripiprazole for the Treatment of Bipolar II and Bipolar NOS Depression.

    abstract:BACKGROUND:Despite initial reports of efficacy in bipolar depression, multicenter trials did not show aripiprazole to be better than placebo, possibly because the doses used were too high, leading to lower efficacy and high dropout rates. This study evaluated the effects of low-dose aripiprazole. Extensive clinical exp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000636

    authors: Kelly T,Lieberman DZ

    更新日期:2017-02-01 00:00:00

  • Specific side effects of long-term imipramine management of panic disorder.

    abstract::In a recent study, the authors suggested that tachycardia, dry mouth, and sweating continued to burden patients with panic disorder with agoraphobia who have shown marked and stable response to 6 months of imipramine treatment at the fixed, weight-adjusted dose of 2.25 mg/kg/day. Although sexual dysfunction and weight...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200204000-00008

    authors: Mavissakalian M,Perel J,Guo S

    更新日期:2002-04-01 00:00:00

  • Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction.

    abstract:OBJECTIVE:The associations between prenatal exposure to antidepressants and preterm delivery and fetal growth restriction are controversial and poorly understood. We studied the relation between antidepressant use and these outcomes. METHODS:Analysis included women with nonmalformed infants interviewed in the Slone Ep...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/JCP.0b013e3181bf344c

    authors: Toh S,Mitchell AA,Louik C,Werler MM,Chambers CD,Hernández-Díaz S

    更新日期:2009-12-01 00:00:00

  • Improving treatment of depression in the elderly: two innovations in statistical design of clinical trials.

    abstract::Depression in the elderly patient may present special challenges for the design of clinical treatment trials due to a complex antidepressant treatment history, individual contraindications to certain medications, medical comorbidity, as well as concurrent medications for other medical conditions. The chronic, relapsin...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.jcp.0000168502.16361.ad

    authors: Lavori PW

    更新日期:2005-08-01 00:00:00

  • Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

    abstract:INTRODUCTION:One of the major enzymes of the cytochrome P450 drug-metabolizing system, CYP2D6, shows a high degree of genetic polymorphism and variability in activity. Based on the degree of CYP2D6 activity, individuals can be broadly classified as poor metabolizers (PMs) or extensive metabolizers (EMs); the metabolism...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3181acc4dd

    authors: Nichols AI,Lobello K,Guico-Pabia CJ,Paul J,Preskorn SH

    更新日期:2009-08-01 00:00:00

  • The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.

    abstract::In this study, the authors investigated the relationship between the metabolism of clomipramine (C) and the genotypes of cytochrome P450 (CYP) CYP2C19 and CYP2D6. Fifty-one Japanese patients (18 men and 33 women) were administered 10 to 250 mg/day of C by mouth and maintained on the same daily dose of C for at least 2...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-200112000-00002

    authors: Yokono A,Morita S,Someya T,Hirokane G,Okawa M,Shimoda K

    更新日期:2001-12-01 00:00:00

  • Novel antipsychotics and severe hyperlipidemia.

    abstract::Newer atypical antipsychotics demonstrate superior effectiveness, with a diminished incidence of extrapyramidal side effects compared with older typical antipsychotics, but they have been associated with the development of obesity and new-onset diabetes. A small number of reports documenting modest hypertriglyceridemi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-200108000-00003

    authors: Meyer JM

    更新日期:2001-08-01 00:00:00

  • Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.

    abstract:BACKGROUND:Pharmacokinetic-pharmacodynamic (PK/PD) models were developed to describe the relationship between the time course of paliperidone plasma concentrations and the risk of relapse of schizophrenia symptoms following administration of paliperidone palmitate 1-month (PP1M) and 3-month (PP3M) long-acting injectabl...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/JCP.0000000000001137

    authors: Russu A,Savitz A,Mathews M,Gopal S,Feng Y,Samtani MN

    更新日期:2019-11-01 00:00:00

  • Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.

    abstract::Patients with major depressive disorder remain at risk for relapse following remission and often continue to experience subthreshold symptoms. This study compared the rate of relapse of major depressive disorder and the prevalence of residual depressive symptoms during the continuation phase for patients treated with ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200210000-00006

    authors: Perlis RH,Nierenberg AA,Alpert JE,Pava J,Matthews JD,Buchin J,Sickinger AH,Fava M

    更新日期:2002-10-01 00:00:00

  • Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone With Olanzapine as a Comparator.

    abstract:PURPOSE/BACKGROUND:Extensive research has been conducted comparing the metabolic characteristics of older second-generation antipsychotics (SGAs); minimal data exist comparing the long-term metabolic effects of SGAs approved in the last 10 years. METHODS/PROCEDURES:A retrospective chart review of patients treated with...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001318

    authors: Greger J,Aladeen T,Lewandowski E,Wojcik R,Westphal E,Rainka M,Capote H

    更新日期:2021-01-01 00:00:00

  • Risk of Mortality Among Patients Treated With Antipsychotic Medications: A Nationwide Population-Based Study in Taiwan.

    abstract::In this nationwide population-based study, we examined whether haloperidol exposure is associated with a higher risk of mortality than are other antipsychotic medications. Patients who newly received monotherapy with chlorpromazine (n = 2133), haloperidol (n = 4454), quetiapine (n = 1513), and risperidone (n = 1046) b...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000451

    authors: Wang LJ,Lee SY,Yuan SS,Yang KC,Yang CJ,Lee TL,Shyu YC

    更新日期:2016-02-01 00:00:00

  • Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.

    abstract::Switching antipsychotic regimen to agents with low weight gain potential has been suggested in patients who gain excessive weight on their antipsychotic therapy. In an open-label pilot study, we evaluated the metabolic and psychiatric efficacy of switching to aripiprazole in 15 (9 men, 6 women) outpatients with schizo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3180a9076c

    authors: Kim SH,Ivanova O,Abbasi FA,Lamendola CA,Reaven GM,Glick ID

    更新日期:2007-08-01 00:00:00

  • Interrater reliability of the modified Monitoring of Side Effects Scale for assessment of adverse effects of psychiatric medication in clinical and research settings.

    abstract::The assessment of adverse effects of psychiatric medications is important in clinical and research settings because they are often associated with medication discontinuation, symptom exacerbation, and reduced quality of life. Currently available assessment tools are either limited with regard to the number and variety...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000311

    authors: Nugent KL,Spahr E,Toroney J,Mojtabai R,Nettles C,Turner LW,Fenton A,Spivak A,Cullen BA,Everett A,Eaton WW

    更新日期:2015-06-01 00:00:00

  • 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study.

    abstract:BACKGROUND:Pathological gambling (PG) is a relatively common and highly disabling impulse control disorder. A range of psychotherapeutic agents including selective serotonin reuptake inhibitors, antiepileptic drugs, and opioid antagonists are shown to be effective in the short-term treatment of PG. The use of a wide ra...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/jcp.0b013e31815a4400

    authors: Dannon PN,Lowengrub K,Musin E,Gonopolsky Y,Kotler M

    更新日期:2007-12-01 00:00:00

  • Efficacy of antidepressant medications in children and adolescents with obsessive-compulsive disorder: a systematic appraisal.

    abstract::The aim of this article was to analyze systematically literature information published in English (between 1966 and January 2011) on the efficacy of antidepressants in pediatric obsessive-compulsive disorder. Data were identified through different databases by using variously combined patterns of search terms. Searche...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/JCP.0b013e31822bb1ff

    authors: Gentile S

    更新日期:2011-10-01 00:00:00

  • Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial.

    abstract::A double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 weeks of treatment with risperidone in the management of 48 adolescent and adult patients with Tourette syndrome. Twenty-four patients were randomly assigned to treatment with risperidone in doses of 0.5 to 6.0 mg/da...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200202000-00006

    authors: Dion Y,Annable L,Sandor P,Chouinard G

    更新日期:2002-02-01 00:00:00

  • Aripiprazole in schizophrenia with cocaine dependence: a pilot study.

    abstract::The debilitation of schizophrenia (SCHZ) worsens markedly with comorbid cocaine dependence (CD) and alcohol abuse. To date, no medications have conclusively demonstrated effects against both SCHZ and CD (SCHZ + CD) simultaneously. Because of its dopamine-modulating properties, we hypothesized that aripiprazole would a...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.jcp.0000169419.38899.5b

    authors: Beresford TP,Clapp L,Martin B,Wiberg JL,Alfers J,Beresford HF

    更新日期:2005-08-01 00:00:00

  • Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived?

    abstract::In a double-blind, parallel groups study, 60 healthy student volunteers (29 men and 31 women, aged 19-22 years) were randomly allocated to receive placebo, 100 or 200 mg modafinil. Two hours later, in the early evening, they completed an extensive cognitive battery. The 3 groups did not differ in self-ratings of sleep...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000155816.21467.25

    authors: Randall DC,Viswanath A,Bharania P,Elsabagh SM,Hartley DE,Shneerson JM,File SE

    更新日期:2005-04-01 00:00:00

  • Haloperidol blood levels in acute mania with psychosis.

    abstract::In this study, the authors examined the relationship between steady-state haloperidol blood levels and clinical response in patients with acute psychotic mania. Fifty-four inpatients with acute mania were randomly assigned to receive either haloperidol 25 mg/day or haloperidol 5 mg/day. Each subject also received a co...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200108000-00013

    authors: Chou JC,Czobor P,Dacpano G,Richardson N,Tuma I,Trujillo M,Cooper TB,Volavka J

    更新日期:2001-08-01 00:00:00

  • A Phase 2 Randomized Dose-Finding Study With Esmirtazapine in Patients With Primary Insomnia.

    abstract::The antidepressant mirtazapine is an alternative to classical hypnotics, and this study investigated the efficacy and safety of esmirtazapine (Org 50081, the maleic acid salt of S-mirtazapine) in patients given a diagnosis of primary insomnia after acute (2-day) treatment. Patients aged 18 to 65 years with primary ins...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/JCP.0000000000000546

    authors: Ruwe F,IJzerman-Boon P,Roth T,Zammit G,Ivgy-May N

    更新日期:2016-10-01 00:00:00

  • Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance.

    abstract::The aims of this study were to examine whether pindolol, a serotonin (5-hydroxytryptamine [5-HT])-1A receptor antagonist, and mianserin, a 5-HT2A/C and alpha2-adrenoceptor (alpha2-AR) antagonist, may augment the clinical efficacy of fluoxetine, a selective serotonin reuptake inhibitor, and shorten the latency of onset...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199904000-00014

    authors: Maes M,Libbrecht I,van Hunsel F,Campens D,Meltzer HY

    更新日期:1999-04-01 00:00:00

  • Tiaspirone in schizophrenia.

    abstract::It was predicted that tiaspirone, a novel compound, would benefit schizophrenic patients since in animal experiments it is a potent dopamine blocker. Following a placebo washout period of 1 to 2 weeks, 14 patients were treated for 28 days with the drug in a single-blind, dose ranging trial. GAS, NOSIE, and BPRS scores...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Moore NC,Meyendorff E,Yeragani V,LeWitt PA,Gershon S

    更新日期:1987-04-01 00:00:00